Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S9WW
|
|||
| Former ID |
DNCL002224
|
|||
| Drug Name |
GI-6301
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Chordoma [ICD-11: 5A61.0] | Phase 2 | [1], [2] | |
| Advanced cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-C96; ICD-9: 140-229] | Phase 1 | [1], [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [3] | ||
| Company |
GlobeImmune
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-box transcription factor T (TBXT) | Target Info | . | [4] |
| Panther Pathway | Wnt signaling pathway | |||
| Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | |||
| Validated transcriptional targets of deltaNp63 isoforms | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT01519817) Open Label Study to Evaluate the Safety and Tolerability of GI-6301 (Whole Heat-Killed Recombinant Yeast Modified to Express Brachyury Protein) in Adults With Solid Tumors. U.S. National Institutes of Health. | |||
| REF 4 | Clinical pipeline report, company report or official report of GlobeImmune. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.